ID;Description;GeneRatio;BgRatio;pvalue;p.adjust;qvalue;geneID;Count
GO:0060337;type I interferon signaling pathway;25/26;95/18862;2.92637565935164e-58;1.12564898002311e-55;7.3509220229055e-56;STAT1/MX2/IFIT2/OAS1/IFITM1/IFIT3/OAS3/IFI35/IRF2/IRF9/IFI6/XAF1/SAMHD1/MX1/RSAD2/IRF1/PSMB8/IFIT1/IFITM3/GBP2/BST2/OAS2/IFI27/ADAR/OASL;25
GO:0071357;cellular response to type I interferon;25/26;96/18862;3.95658692451004e-58;1.12564898002311e-55;7.3509220229055e-56;STAT1/MX2/IFIT2/OAS1/IFITM1/IFIT3/OAS3/IFI35/IRF2/IRF9/IFI6/XAF1/SAMHD1/MX1/RSAD2/IRF1/PSMB8/IFIT1/IFITM3/GBP2/BST2/OAS2/IFI27/ADAR/OASL;25
GO:0034340;response to type I interferon;25/26;101/18862;1.69590647035428e-57;3.21656927210528e-55;2.10054380363179e-55;STAT1/MX2/IFIT2/OAS1/IFITM1/IFIT3/OAS3/IFI35/IRF2/IRF9/IFI6/XAF1/SAMHD1/MX1/RSAD2/IRF1/PSMB8/IFIT1/IFITM3/GBP2/BST2/OAS2/IFI27/ADAR/OASL;25
GO:0051607;defense response to virus;22/26;260/18862;6.73555279994697e-38;7.66505908633965e-36;5.00557923869743e-36;STAT1/MX2/IFIT2/OAS1/IFITM1/IFIT3/OAS3/IRF2/IRF9/IFI6/SAMHD1/MX1/RSAD2/IRF1/IFIT1/IFITM3/IFIT5/BST2/OAS2/IFI27/ADAR/OASL;22
GO:0140546;defense response to symbiont;22/26;260/18862;6.73555279994697e-38;7.66505908633965e-36;5.00557923869743e-36;STAT1/MX2/IFIT2/OAS1/IFITM1/IFIT3/OAS3/IRF2/IRF9/IFI6/SAMHD1/MX1/RSAD2/IRF1/IFIT1/IFITM3/IFIT5/BST2/OAS2/IFI27/ADAR/OASL;22
GO:0009615;response to virus;22/26;359/18862;1.03259135348201e-34;9.79240800218776e-33;6.39482013647633e-33;STAT1/MX2/IFIT2/OAS1/IFITM1/IFIT3/OAS3/IRF2/IRF9/IFI6/SAMHD1/MX1/RSAD2/IRF1/IFIT1/IFITM3/IFIT5/BST2/OAS2/IFI27/ADAR/OASL;22
GO:0045069;regulation of viral genome replication;12/26;83/18862;2.11155158024951e-22;1.7163897845171e-20;1.12086873357605e-20;OAS1/IFITM1/OAS3/MX1/RSAD2/IFIT1/IFITM3/IFIT5/BST2/OAS2/ADAR/OASL;12
GO:0045071;negative regulation of viral genome replication;11/26;54/18862;2.66868667703565e-22;1.89810339904161e-20;1.2395347328863e-20;OAS1/IFITM1/OAS3/MX1/RSAD2/IFIT1/IFITM3/IFIT5/BST2/OAS2/OASL;11
GO:0019079;viral genome replication;13/26;129/18862;3.71540469787497e-22;2.3489614145454e-20;1.53396240742674e-20;OAS1/IFITM1/OAS3/MX1/RSAD2/IFIT1/IFITM3/IFIT5/BST2/OAS2/IFI27/ADAR/OASL;13
GO:0048525;negative regulation of viral process;12/26;89/18862;5.15400244267576e-22;2.93262738988251e-20;1.91511880238373e-20;STAT1/OAS1/IFITM1/OAS3/MX1/RSAD2/IFIT1/IFITM3/IFIT5/BST2/OAS2/OASL;12
GO:0050792;regulation of viral process;13/26;186/18862;5.07237599414224e-20;2.62380176424267e-18;1.71344375687293e-18;STAT1/OAS1/IFITM1/OAS3/MX1/RSAD2/IFIT1/IFITM3/IFIT5/BST2/OAS2/ADAR/OASL;13
GO:0043903;regulation of biological process involved in symbiotic interaction;13/26;197/18862;1.08931470071308e-19;5.16516720588119e-18;3.37305341536594e-18;STAT1/OAS1/IFITM1/OAS3/MX1/RSAD2/IFIT1/IFITM3/IFIT5/BST2/OAS2/ADAR/OASL;13
GO:1903900;regulation of viral life cycle;12/26;148/18862;3.04059437582653e-19;1.33084476911177e-17;8.69092967341511e-18;OAS1/IFITM1/OAS3/MX1/RSAD2/IFIT1/IFITM3/IFIT5/BST2/OAS2/ADAR/OASL;12
GO:0034341;response to interferon-gamma;12/26;197/18862;1.02138144163153e-17;4.15118600205959e-16;2.7108845781649e-16;STAT1/OAS1/IFITM1/OAS3/IRF2/IRF9/IRF1/IFITM3/GBP2/BST2/OAS2/OASL;12
GO:0019058;viral life cycle;13/26;348/18862;1.92435112659384e-16;7.29970527354595e-15;4.76698910657982e-15;OAS1/IFITM1/OAS3/MX1/RSAD2/IFIT1/IFITM3/IFIT5/BST2/OAS2/IFI27/ADAR/OASL;13
GO:0035455;response to interferon-alpha;7/26;21/18862;4.48780813515536e-16;1.59597676806463e-14;1.04223438928279e-14;MX2/IFIT2/IFITM1/IFIT3/IFITM3/BST2/ADAR;7
GO:0060333;interferon-gamma-mediated signaling pathway;9/26;91/18862;2.75624624976235e-15;9.22531833008692e-14;6.02448870691089e-14;STAT1/OAS1/OAS3/IRF2/IRF9/IRF1/GBP2/OAS2/OASL;9
GO:0071346;cellular response to interferon-gamma;9/26;177/18862;1.25277364539718e-12;3.96015669017218e-11;2.58613506915323e-11;STAT1/OAS1/OAS3/IRF2/IRF9/IRF1/GBP2/OAS2/OASL;9
GO:0035456;response to interferon-beta;6/26;31/18862;2.65141860265327e-12;7.94030097320901e-11;5.18532280740501e-11;STAT1/IFITM1/XAF1/IRF1/IFITM3/BST2;6
GO:0032069;regulation of nuclease activity;4/26;22/18862;2.03964420475652e-08;5.80278776253229e-07;3.78944423304763e-07;OAS1/OAS3/OAS2/OASL;4
GO:0002831;regulation of response to biotic stimulus;7/26;420/18862;1.17784058156599e-06;3.19138709957641e-05;2.08409887364808e-05;STAT1/IFI35/SAMHD1/IRF1/PSMB8/IFIT1/ADAR;7
GO:0045088;regulation of innate immune response;6/26;315/18862;3.59313062688488e-06;9.29314239407953e-05;6.068780436796e-05;STAT1/IFI35/SAMHD1/IRF1/PSMB8/ADAR;6
GO:1903901;negative regulation of viral life cycle;3/26;24/18862;4.61632777365182e-06;0.000114203934922082;7.45795745583109e-05;IFITM1/IFITM3/BST2;3
GO:0035457;cellular response to interferon-alpha;2/26;11/18862;9.97257100867994e-05;0.00226975716157555;0.00148223897518485;IFIT2/IFIT3;2
GO:0070142;synaptic vesicle budding;2/26;11/18862;9.97257100867994e-05;0.00226975716157555;0.00148223897518485;MX2/MX1;2
GO:0034121;regulation of toll-like receptor signaling pathway;3/26;77/18862;0.000158948346689764;0.00347852343332599;0.00227160997495898;IFI35/RSAD2/IRF1;3
GO:0060339;negative regulation of type I interferon-mediated signaling pathway;2/26;15/18862;0.000189740659722976;0.00385580126365619;0.00251798695045904;SAMHD1/ADAR;2
GO:0090148;membrane fission;2/26;15/18862;0.000189740659722976;0.00385580126365619;0.00251798695045904;MX2/MX1;2
GO:0002566;somatic diversification of immune receptors via somatic mutation;2/26;16/18862;0.0002166626644416;0.0042510708988714;0.00277611326852577;SAMHD1/ADAR;2
GO:0098884;postsynaptic neurotransmitter receptor internalization;2/26;18/18862;0.000275776840149746;0.00506183942081308;0.00330557638617522;MX2/MX1;2
GO:0140239;postsynaptic endocytosis;2/26;18/18862;0.000275776840149746;0.00506183942081308;0.00330557638617522;MX2/MX1;2
GO:0046597;negative regulation of viral entry into host cell;2/26;20/18862;0.000341887786684453;0.00607919220698293;0.00396994699669776;IFITM1/IFITM3;2
GO:0062207;regulation of pattern recognition receptor signaling pathway;3/26;105/18862;0.000397046628015804;0.0068460464042725;0.00447073236649374;IFI35/RSAD2/IRF1;3
GO:0035458;cellular response to interferon-beta;2/26;22/18862;0.00041495947912852;0.00694446893012141;0.00453500607220952;STAT1/IRF1;2
GO:0099590;neurotransmitter receptor internalization;2/26;25/18862;0.000537539937450223;0.00873886355454791;0.00570681497503545;MX2/MX1;2
GO:0034123;positive regulation of toll-like receptor signaling pathway;2/26;27/18862;0.000627856753129073;0.0099236247925123;0.00648050976182932;IFI35/RSAD2;2
GO:0045070;positive regulation of viral genome replication;2/26;31/18862;0.000828962046406793;0.0127480920109585;0.00832499580032996;IFIT1/ADAR;2
GO:0060338;regulation of type I interferon-mediated signaling pathway;2/26;35/18862;0.00105712732347954;0.0158290907121015;0.010337006791919;SAMHD1/ADAR;2
GO:0002224;toll-like receptor signaling pathway;3/26;157/18862;0.00127798095728885;0.0186454144794194;0.0121761748427251;IFI35/RSAD2/IRF1;3
GO:0046596;regulation of viral entry into host cell;2/26;41/18862;0.00144949889677967;0.0206016751837157;0.0134536885391761;IFITM1/IFITM3;2
GO:0000266;mitochondrial fission;2/26;42/18862;0.00152068604168025;0.0206016751837157;0.0134536885391761;MX2/MX1;2
GO:0062208;positive regulation of pattern recognition receptor signaling pathway;2/26;42/18862;0.00152068604168025;0.0206016751837157;0.0134536885391761;IFI35/RSAD2;2
GO:0048489;synaptic vesicle transport;2/26;43/18862;0.00159351646361482;0.0210862992510892;0.0137701667480057;MX2/MX1;2
GO:0001959;regulation of cytokine-mediated signaling pathway;3/26;177/18862;0.00180206515492332;0.023035956299167;0.015043368002231;STAT1/SAMHD1/ADAR;3
GO:0099637;neurotransmitter receptor transport;2/26;46/18862;0.00182182431188491;0.023035956299167;0.015043368002231;MX2/MX1;2
GO:0052372;modulation by symbiont of entry into host;2/26;48/18862;0.00198216708913066;0.0245185450807684;0.0160115556627717;IFITM1/IFITM3;2
GO:0002683;negative regulation of immune system process;4/26;403/18862;0.00211471177788271;0.0256015106726651;0.0167187739662396;SAMHD1/IRF1/BST2/ADAR;4
GO:0060759;regulation of response to cytokine stimulus;3/26;189/18862;0.00217248266708867;0.0257529716161136;0.0168176838044364;STAT1/SAMHD1/ADAR;3
GO:0097479;synaptic vesicle localization;2/26;54/18862;0.00250187985695935;0.029052441604283;0.01897236497329;MX2/MX1;2
GO:0002221;pattern recognition receptor signaling pathway;3/26;208/18862;0.00285020112267811;0.0324352887760769;0.0211814946590605;IFI35/RSAD2/IRF1;3
GO:0048488;synaptic vesicle endocytosis;2/26;59/18862;0.00297879463929539;0.0325948874953668;0.0212857187787707;MX2/MX1;2
GO:0140238;presynaptic endocytosis;2/26;59/18862;0.00297879463929539;0.0325948874953668;0.0212857187787707;MX2/MX1;2
GO:0099072;regulation of postsynaptic membrane neurotransmitter receptor levels;2/26;60/18862;0.00307890751342567;0.0330546863233813;0.021585985148744;MX2/MX1;2
GO:0051701;biological process involved in interaction with host;3/26;219/18862;0.00329596443997682;0.0347296993767927;0.0226798332809321;IFITM1/IFIT1/IFITM3;3
GO:0002697;regulation of immune effector process;4/26;465/18862;0.00354439539469855;0.0364193687827052;0.0237832525766255;STAT1/RSAD2/IFIT1/BST2;4
GO:0045824;negative regulation of innate immune response;2/26;65/18862;0.00360289168112411;0.0364193687827052;0.0237832525766255;SAMHD1/ADAR;2
GO:0044766;multi-organism transport;2/26;66/18862;0.00371234339085571;0.0364193687827052;0.0237832525766255;IFIT1/BST2;2
GO:1902579;multi-organism localization;2/26;66/18862;0.00371234339085571;0.0364193687827052;0.0237832525766255;IFIT1/BST2;2
GO:0050688;regulation of defense response to virus;2/26;69/18862;0.00404993383454011;0.0390578364720902;0.0255062737483079;STAT1/IFIT1;2
GO:0098586;cellular response to virus;2/26;71/18862;0.00428264908292647;0.040613788803086;0.0265223706363692;IFI6/ADAR;2
GO:0036465;synaptic vesicle recycling;2/26;72/18862;0.00440129089029448;0.0409511913310764;0.0267427075013781;MX2/MX1;2
GO:0043122;regulation of I-kappaB kinase/NF-kappaB signaling;3/26;244/18862;0.00446216847544242;0.0409511913310764;0.0267427075013781;STAT1/IFIT5/BST2;3
GO:0002200;somatic diversification of immune receptors;2/26;75/18862;0.00476630404097488;0.0430480476081699;0.0281120355298936;SAMHD1/ADAR;2
GO:0001960;negative regulation of cytokine-mediated signaling pathway;2/26;76/18862;0.00489099076623359;0.0434839647810455;0.0283967062579023;SAMHD1/ADAR;2
GO:0032481;positive regulation of type I interferon production;2/26;77/18862;0.00501717856408809;0.0439196092764019;0.0286811989169732;STAT1/IRF1;2
GO:0060761;negative regulation of response to cytokine stimulus;2/26;81/18862;0.00553685964322545;0.0477344414696254;0.0311724314841879;SAMHD1/ADAR;2
GO:0002718;regulation of cytokine production involved in immune response;2/26;84/18862;0.00594218413647323;0.0504642205022876;0.0329550824850754;RSAD2/BST2;2
GO:0007249;I-kappaB kinase/NF-kappaB signaling;3/26;282/18862;0.00666546052097419;0.055774221124034;0.0364227177074905;STAT1/IFIT5/BST2;3
GO:0002440;production of molecular mediator of immune response;3/26;286/18862;0.00692892620274483;0.0564055180723854;0.0368349789650394;SAMHD1/RSAD2/BST2;3
GO:0048524;positive regulation of viral process;2/26;91/18862;0.00693916742542527;0.0564055180723854;0.0368349789650394;IFIT1/ADAR;2
GO:0002367;cytokine production involved in immune response;2/26;93/18862;0.0072370494201259;0.0579983256345301;0.0378751437406144;RSAD2/BST2;2
GO:0071356;cellular response to tumor necrosis factor;3/26;296/18862;0.00761462396369649;0.059975813381692;0.0391665195148224;STAT1/PSMB8/GBP2;3
GO:0032091;negative regulation of protein binding;2/26;96/18862;0.00769461226162305;0.059975813381692;0.0391665195148224;IFIT2/IFIT1;2
GO:0002832;negative regulation of response to biotic stimulus;2/26;100/18862;0.00832457956708052;0.0640092672117407;0.0418005204435195;SAMHD1/ADAR;2
GO:0046822;regulation of nucleocytoplasmic transport;2/26;103/18862;0.00881183161863338;0.0668524292133652;0.0436572148965275;MX2/IFI27;2
GO:0034612;response to tumor necrosis factor;3/26;320/18862;0.00942065234276172;0.0700609320619815;0.0457524910144843;STAT1/PSMB8/GBP2;3
GO:0046632;alpha-beta T cell differentiation;2/26;107/18862;0.00948100486603265;0.0700609320619815;0.0457524910144843;RSAD2/IRF1;2
GO:0006900;vesicle budding from membrane;2/26;109/18862;0.00982388118858471;0.0716639537987782;0.0467993260400864;MX2/MX1;2
GO:0031623;receptor internalization;2/26;111/18862;0.0101722432455654;0.0732659038826168;0.0478454612349713;MX2/MX1;2
GO:0030218;erythrocyte differentiation;2/26;115/18862;0.0108853030587136;0.0774217180051007;0.0505593681542883;STAT1/ADAR;2
GO:0008637;apoptotic mitochondrial changes;2/26;118/18862;0.0114342726697157;0.08032223640825;0.052453518549833;IFIT2/IFI6;2
GO:0034101;erythrocyte homeostasis;2/26;121/18862;0.0119952793889961;0.0832355362480338;0.0543560157165034;STAT1/ADAR;2
GO:0032479;regulation of type I interferon production;2/26;128/18862;0.013350540957029;0.0906588193404925;0.0592037059054553;STAT1/IRF1;2
GO:0032606;type I interferon production;2/26;129/18862;0.0135493807127114;0.0906588193404925;0.0592037059054553;STAT1/IRF1;2
GO:0071104;response to interleukin-9;1/26;10/18862;0.0137023874574382;0.0906588193404925;0.0592037059054553;STAT1;1
GO:0072203;cell proliferation involved in metanephros development;1/26;10/18862;0.0137023874574382;0.0906588193404925;0.0592037059054553;STAT1;1
GO:0034145;positive regulation of toll-like receptor 4 signaling pathway;1/26;11/18862;0.0150626536321736;0.0941829661176571;0.0615051096837165;IFI35;1
GO:0034163;regulation of toll-like receptor 9 signaling pathway;1/26;11/18862;0.0150626536321736;0.0941829661176571;0.0615051096837165;RSAD2;1
GO:0070106;interleukin-27-mediated signaling pathway;1/26;11/18862;0.0150626536321736;0.0941829661176571;0.0615051096837165;STAT1;1
GO:0070757;interleukin-35-mediated signaling pathway;1/26;11/18862;0.0150626536321736;0.0941829661176571;0.0615051096837165;STAT1;1
GO:2000551;regulation of T-helper 2 cell cytokine production;1/26;11/18862;0.0150626536321736;0.0941829661176571;0.0615051096837165;RSAD2;1
GO:0046718;viral entry into host cell;2/26;140/18862;0.0158213978281412;0.0973293219866768;0.0635598014268743;IFITM1/IFITM3;2
GO:0002730;regulation of dendritic cell cytokine production;1/26;12/18862;0.016421115836065;0.0973293219866768;0.0635598014268743;BST2;1
GO:0003337;mesenchymal to epithelial transition involved in metanephros morphogenesis;1/26;12/18862;0.016421115836065;0.0973293219866768;0.0635598014268743;STAT1;1
GO:0034154;toll-like receptor 7 signaling pathway;1/26;12/18862;0.016421115836065;0.0973293219866768;0.0635598014268743;RSAD2;1
GO:0051095;regulation of helicase activity;1/26;12/18862;0.016421115836065;0.0973293219866768;0.0635598014268743;IFIT1;1
GO:0002262;myeloid cell homeostasis;2/26;145/18862;0.0169046937695505;0.0991625851017961;0.0647569929533513;STAT1/ADAR;2
GO:0002700;regulation of production of molecular mediator of immune response;2/26;146/18862;0.0171250839894327;0.0992606704606967;0.0648210464760447;RSAD2/BST2;2
GO:0002371;dendritic cell cytokine production;1/26;13/18862;0.0177777763659464;0.0992606704606967;0.0648210464760447;BST2;1
GO:0035745;T-helper 2 cell cytokine production;1/26;13/18862;0.0177777763659464;0.0992606704606967;0.0648210464760447;RSAD2;1
GO:0072182;regulation of nephron tubule epithelial cell differentiation;1/26;13/18862;0.0177777763659464;0.0992606704606967;0.0648210464760447;STAT1;1
GO:0046631;alpha-beta T cell activation;2/26;149/18862;0.0177936527012145;0.0992606704606967;0.0648210464760447;RSAD2/IRF1;2
GO:0050777;negative regulation of immune response;2/26;150/18862;0.0180189631584523;0.0995416508462073;0.0650045375057094;SAMHD1/ADAR;2
GO:0044409;entry into host;2/26;153/18862;0.0187022078300654;0.100072064755753;0.0653509182476752;IFITM1/IFITM3;2
GO:0009143;nucleoside triphosphate catabolic process;1/26;14/18862;0.0191326375158474;0.100072064755753;0.0653509182476752;SAMHD1;1
GO:0009151;purine deoxyribonucleotide metabolic process;1/26;14/18862;0.0191326375158474;0.100072064755753;0.0653509182476752;SAMHD1;1
GO:0043374;CD8-positive, alpha-beta T cell differentiation;1/26;14/18862;0.0191326375158474;0.100072064755753;0.0653509182476752;IRF1;1
GO:0051100;negative regulation of binding;2/26;159/18862;0.020101291674479;0.100072064755753;0.0653509182476752;IFIT2/IFIT1;2
GO:0052548;regulation of endopeptidase activity;3/26;426/18862;0.0202351110537205;0.100072064755753;0.0653509182476752;IFI6/PSMB8/BST2;3
GO:0016446;somatic hypermutation of immunoglobulin genes;1/26;15/18862;0.0204857015769995;0.100072064755753;0.0653509182476752;SAMHD1;1
GO:0031054;pre-miRNA processing;1/26;15/18862;0.0204857015769995;0.100072064755753;0.0653509182476752;ADAR;1
GO:0032897;negative regulation of viral transcription;1/26;15/18862;0.0204857015769995;0.100072064755753;0.0653509182476752;IFITM3;1
GO:0061484;hematopoietic stem cell homeostasis;1/26;15/18862;0.0204857015769995;0.100072064755753;0.0653509182476752;ADAR;1
GO:0072075;metanephric mesenchyme development;1/26;15/18862;0.0204857015769995;0.100072064755753;0.0653509182476752;STAT1;1
GO:0072160;nephron tubule epithelial cell differentiation;1/26;15/18862;0.0204857015769995;0.100072064755753;0.0653509182476752;STAT1;1
GO:0072283;metanephric renal vesicle morphogenesis;1/26;15/18862;0.0204857015769995;0.100072064755753;0.0653509182476752;STAT1;1
GO:0002244;hematopoietic progenitor cell differentiation;2/26;161/18862;0.0205772083944167;0.100072064755753;0.0653509182476752;PSMB8/ADAR;2
GO:0001819;positive regulation of cytokine production;3/26;437/18862;0.0216307019844928;0.100861223178577;0.0658662691370596;STAT1/RSAD2/IRF1;3
GO:0002830;positive regulation of type 2 immune response;1/26;16/18862;0.0218369708378362;0.100861223178577;0.0658662691370596;RSAD2;1
GO:0009200;deoxyribonucleoside triphosphate metabolic process;1/26;16/18862;0.0218369708378362;0.100861223178577;0.0658662691370596;SAMHD1;1
GO:0043112;receptor metabolic process;2/26;168/18862;0.0222799974670191;0.100861223178577;0.0658662691370596;MX2/MX1;2
GO:0002819;regulation of adaptive immune response;2/26;170/18862;0.022776990022837;0.100861223178577;0.0658662691370596;RSAD2/IRF1;2
GO:0016246;RNA interference;1/26;17/18862;0.0231864475840008;0.100861223178577;0.0658662691370596;ADAR;1
GO:0061025;membrane fusion;2/26;172/18862;0.0232785910431226;0.100861223178577;0.0658662691370596;MX2/MX1;2
GO:0033209;tumor necrosis factor-mediated signaling pathway;2/26;174/18862;0.0237847734621158;0.100861223178577;0.0658662691370596;STAT1/PSMB8;2
GO:0052547;regulation of peptidase activity;3/26;455/18862;0.0240270272710878;0.100861223178577;0.0658662691370596;IFI6/PSMB8/BST2;3
GO:0052126;movement in host environment;2/26;175/18862;0.0240395742665415;0.100861223178577;0.0658662691370596;IFITM1/IFITM3;2
GO:0051346;negative regulation of hydrolase activity;3/26;456/18862;0.0241642612375048;0.100861223178577;0.0658662691370596;IFI6/IFIT1/BST2;3
GO:0002281;macrophage activation involved in immune response;1/26;18/18862;0.024534134098345;0.100861223178577;0.0658662691370596;IFI35;1
GO:0007221;positive regulation of transcription of Notch receptor target;1/26;18/18862;0.024534134098345;0.100861223178577;0.0658662691370596;STAT1;1
GO:0032780;negative regulation of ATPase activity;1/26;18/18862;0.024534134098345;0.100861223178577;0.0658662691370596;IFIT1;1
GO:0035743;CD4-positive, alpha-beta T cell cytokine production;1/26;18/18862;0.024534134098345;0.100861223178577;0.0658662691370596;RSAD2;1
GO:0071360;cellular response to exogenous dsRNA;1/26;18/18862;0.024534134098345;0.100861223178577;0.0658662691370596;IFIT1;1
GO:0072077;renal vesicle morphogenesis;1/26;18/18862;0.024534134098345;0.100861223178577;0.0658662691370596;STAT1;1
GO:2000696;regulation of epithelial cell differentiation involved in kidney development;1/26;18/18862;0.024534134098345;0.100861223178577;0.0658662691370596;STAT1;1
GO:0099504;synaptic vesicle cycle;2/26;177/18862;0.0245525782628412;0.100861223178577;0.0658662691370596;MX2/MX1;2
GO:0071347;cellular response to interleukin-1;2/26;180/18862;0.0253305400126773;0.100861223178577;0.0658662691370596;PSMB8/GBP2;2
GO:0043123;positive regulation of I-kappaB kinase/NF-kappaB signaling;2/26;182/18862;0.0258547794451549;0.100861223178577;0.0658662691370596;IFIT5/BST2;2
GO:0044827;modulation by host of viral genome replication;1/26;19/18862;0.0258800326609353;0.100861223178577;0.0658662691370596;IFI27;1
GO:0051900;regulation of mitochondrial depolarization;1/26;19/18862;0.0258800326609353;0.100861223178577;0.0658662691370596;IFI6;1
GO:0060216;definitive hemopoiesis;1/26;19/18862;0.0258800326609353;0.100861223178577;0.0658662691370596;ADAR;1
GO:0060231;mesenchymal to epithelial transition;1/26;19/18862;0.0258800326609353;0.100861223178577;0.0658662691370596;STAT1;1
GO:0072074;kidney mesenchyme development;1/26;19/18862;0.0258800326609353;0.100861223178577;0.0658662691370596;STAT1;1
GO:0072087;renal vesicle development;1/26;19/18862;0.0258800326609353;0.100861223178577;0.0658662691370596;STAT1;1
GO:0072234;metanephric nephron tubule development;1/26;19/18862;0.0258800326609353;0.100861223178577;0.0658662691370596;STAT1;1
GO:2001185;regulation of CD8-positive, alpha-beta T cell activation;1/26;19/18862;0.0258800326609353;0.100861223178577;0.0658662691370596;IRF1;1
GO:0038061;NIK/NF-kappaB signaling;2/26;185/18862;0.0266494696207542;0.103153389212307;0.0673631419701126;IFI35/PSMB8;2
GO:0002726;positive regulation of T cell cytokine production;1/26;20/18862;0.0272241455490536;0.103270258782743;0.0674394623074802;RSAD2;1
GO:0016553;base conversion or substitution editing;1/26;20/18862;0.0272241455490536;0.103270258782743;0.0674394623074802;ADAR;1
GO:0043901;negative regulation of multi-organism process;1/26;20/18862;0.0272241455490536;0.103270258782743;0.0674394623074802;BST2;1
GO:0002053;positive regulation of mesenchymal cell proliferation;1/26;21/18862;0.0285664750372039;0.106237413700451;0.0693771289173235;STAT1;1
GO:0072111;cell proliferation involved in kidney development;1/26;21/18862;0.0285664750372039;0.106237413700451;0.0693771289173235;STAT1;1
GO:0072170;metanephric tubule development;1/26;21/18862;0.0285664750372039;0.106237413700451;0.0693771289173235;STAT1;1
GO:0099003;vesicle-mediated transport in synapse;2/26;194/18862;0.029092694091199;0.10635685195598;0.0694551267051352;MX2/MX1;2
GO:0043393;regulation of protein binding;2/26;196/18862;0.0296475150806713;0.10635685195598;0.0694551267051352;IFIT2/IFIT1;2
GO:0010499;proteasomal ubiquitin-independent protein catabolic process;1/26;22/18862;0.029907023397112;0.10635685195598;0.0694551267051352;PSMB8;1
GO:0032727;positive regulation of interferon-alpha production;1/26;22/18862;0.029907023397112;0.10635685195598;0.0694551267051352;STAT1;1
GO:0051882;mitochondrial depolarization;1/26;22/18862;0.029907023397112;0.10635685195598;0.0694551267051352;IFI6;1
GO:0071359;cellular response to dsRNA;1/26;22/18862;0.029907023397112;0.10635685195598;0.0694551267051352;IFIT1;1
GO:0072243;metanephric nephron epithelium development;1/26;22/18862;0.029907023397112;0.10635685195598;0.0694551267051352;STAT1;1
GO:0060149;negative regulation of posttranscriptional gene silencing;1/26;23/18862;0.0312457928977316;0.109746025671662;0.0716683878680912;ADAR;1
GO:0060967;negative regulation of gene silencing by RNA;1/26;23/18862;0.0312457928977316;0.109746025671662;0.0716683878680912;ADAR;1
GO:0070555;response to interleukin-1;2/26;206/18862;0.0324850762277261;0.112205491243996;0.0732745137529008;PSMB8/GBP2;2
GO:0002703;regulation of leukocyte mediated immunity;2/26;209/18862;0.0333566567234381;0.112205491243996;0.0732745137529008;RSAD2/BST2;2
GO:0051650;establishment of vesicle localization;2/26;209/18862;0.0333566567234381;0.112205491243996;0.0732745137529008;MX2/MX1;2
GO:0001562;response to protozoan;1/26;25/18862;0.0339180043830708;0.112205491243996;0.0732745137529008;GBP2;1
GO:0042832;defense response to protozoan;1/26;25/18862;0.0339180043830708;0.112205491243996;0.0732745137529008;GBP2;1
GO:0060330;regulation of response to interferon-gamma;1/26;25/18862;0.0339180043830708;0.112205491243996;0.0732745137529008;STAT1;1
GO:0060334;regulation of interferon-gamma-mediated signaling pathway;1/26;25/18862;0.0339180043830708;0.112205491243996;0.0732745137529008;STAT1;1
GO:0072202;cell differentiation involved in metanephros development;1/26;25/18862;0.0339180043830708;0.112205491243996;0.0732745137529008;STAT1;1
GO:0072207;metanephric epithelium development;1/26;25/18862;0.0339180043830708;0.112205491243996;0.0732745137529008;STAT1;1
GO:0072273;metanephric nephron morphogenesis;1/26;25/18862;0.0339180043830708;0.112205491243996;0.0732745137529008;STAT1;1
GO:0050803;regulation of synapse structure or activity;2/26;214/18862;0.0348297446581934;0.11268581773858;0.0735881854809341;MX2/MX1;2
GO:0002719;negative regulation of cytokine production involved in immune response;1/26;26/18862;0.0352514508918582;0.11268581773858;0.0735881854809341;BST2;1
GO:0009264;deoxyribonucleotide catabolic process;1/26;26/18862;0.0352514508918582;0.11268581773858;0.0735881854809341;SAMHD1;1
GO:0010464;regulation of mesenchymal cell proliferation;1/26;26/18862;0.0352514508918582;0.11268581773858;0.0735881854809341;STAT1;1
GO:0034143;regulation of toll-like receptor 4 signaling pathway;1/26;26/18862;0.0352514508918582;0.11268581773858;0.0735881854809341;IFI35;1
GO:0034162;toll-like receptor 9 signaling pathway;1/26;26/18862;0.0352514508918582;0.11268581773858;0.0735881854809341;RSAD2;1
GO:0097191;extrinsic apoptotic signaling pathway;2/26;217/18862;0.0357257320609067;0.113563919232715;0.0741616196265808;IFI6/IFI27;2
GO:0036037;CD8-positive, alpha-beta T cell activation;1/26;27/18862;0.0365831275895019;0.115004417670865;0.0751023206693467;IRF1;1
GO:0046386;deoxyribose phosphate catabolic process;1/26;27/18862;0.0365831275895019;0.115004417670865;0.0751023206693467;SAMHD1;1
GO:0001649;osteoblast differentiation;2/26;223/18862;0.0375446189638264;0.115981279032346;0.0757402488177191;IFITM1/ADAR;2
GO:0045089;positive regulation of innate immune response;2/26;223/18862;0.0375446189638264;0.115981279032346;0.0757402488177191;IFI35/PSMB8;2
GO:0051648;vesicle localization;2/26;224/18862;0.0378512194611996;0.115981279032346;0.0757402488177191;MX2/MX1;2
GO:0032607;interferon-alpha production;1/26;28/18862;0.0379130367311359;0.115981279032346;0.0757402488177191;STAT1;1
GO:0032647;regulation of interferon-alpha production;1/26;28/18862;0.0379130367311359;0.115981279032346;0.0757402488177191;STAT1;1
GO:0098657;import into cell;2/26;230/18862;0.0397112604974054;0.120832658946651;0.0789083870283371;MX2/MX1;2
GO:0002828;regulation of type 2 immune response;1/26;30/18862;0.0405675613531479;0.121489170578638;0.0793371144468764;RSAD2;1
GO:0070102;interleukin-6-mediated signaling pathway;1/26;30/18862;0.0405675613531479;0.121489170578638;0.0793371144468764;STAT1;1
GO:0090183;regulation of kidney development;1/26;30/18862;0.0405675613531479;0.121489170578638;0.0793371144468764;STAT1;1
GO:0031348;negative regulation of defense response;2/26;236/18862;0.0416058659903457;0.122869335962846;0.0802384156782623;SAMHD1/ADAR;2
GO:0002230;positive regulation of defense response to virus by host;1/26;31/18862;0.0418921813300389;0.122869335962846;0.0802384156782623;STAT1;1
GO:0003338;metanephros morphogenesis;1/26;31/18862;0.0418921813300389;0.122869335962846;0.0802384156782623;STAT1;1
GO:0044788;modulation by host of viral process;1/26;31/18862;0.0418921813300389;0.122869335962846;0.0802384156782623;IFI27;1
GO:0070663;regulation of leukocyte proliferation;2/26;241/18862;0.0432106397548949;0.123564619705073;0.0806924627802991;IRF1/BST2;2
GO:0045648;positive regulation of erythrocyte differentiation;1/26;32/18862;0.0432150427439534;0.123564619705073;0.0806924627802991;STAT1;1
GO:0046825;regulation of protein export from nucleus;1/26;32/18862;0.0432150427439534;0.123564619705073;0.0806924627802991;IFI27;1
GO:1901099;negative regulation of signal transduction in absence of ligand;1/26;32/18862;0.0432150427439534;0.123564619705073;0.0806924627802991;IFI6;1
GO:2001240;negative regulation of extrinsic apoptotic signaling pathway in absence of ligand;1/26;32/18862;0.0432150427439534;0.123564619705073;0.0806924627802991;IFI6;1
GO:0010951;negative regulation of endopeptidase activity;2/26;245/18862;0.0445111677079116;0.124832847876097;0.0815206646938532;IFI6/BST2;2
GO:0002724;regulation of T cell cytokine production;1/26;33/18862;0.0445361478362878;0.124832847876097;0.0815206646938532;RSAD2;1
GO:0032728;positive regulation of interferon-beta production;1/26;33/18862;0.0445361478362878;0.124832847876097;0.0815206646938532;IRF1;1
GO:0045589;regulation of regulatory T cell differentiation;1/26;33/18862;0.0445361478362878;0.124832847876097;0.0815206646938532;IRF1;1
GO:0030217;T cell differentiation;2/26;246/18862;0.0448385958311507;0.125064514842768;0.0816719521589071;RSAD2/IRF1;2
GO:0048872;homeostasis of number of cells;2/26;249/18862;0.0458263440877106;0.12665912059808;0.0827132912239799;STAT1/ADAR;2
GO:0046640;regulation of alpha-beta T cell proliferation;1/26;34/18862;0.0458554988457022;0.12665912059808;0.0827132912239799;IRF1;1
GO:0002755;MyD88-dependent toll-like receptor signaling pathway;1/26;35/18862;0.0471730980081204;0.129669047181742;0.0846788893814722;IRF1;1
GO:0002369;T cell cytokine production;1/26;36/18862;0.0484889475567358;0.130171892790358;0.0850072669595714;RSAD2;1
GO:0009394;2'-deoxyribonucleotide metabolic process;1/26;36/18862;0.0484889475567358;0.130171892790358;0.0850072669595714;SAMHD1;1
GO:0042092;type 2 immune response;1/26;36/18862;0.0484889475567358;0.130171892790358;0.0850072669595714;RSAD2;1
GO:0045066;regulatory T cell differentiation;1/26;36/18862;0.0484889475567358;0.130171892790358;0.0850072669595714;IRF1;1
GO:0010466;negative regulation of peptidase activity;2/26;257/18862;0.0484998967865657;0.130171892790358;0.0850072669595714;IFI6/BST2;2
GO:0002833;positive regulation of response to biotic stimulus;2/26;258/18862;0.0488380845694461;0.130464178967206;0.0851981411070643;IFI35/PSMB8;2
GO:0046633;alpha-beta T cell proliferation;1/26;37/18862;0.049803049722014;0.131194144869565;0.0856748369974217;IRF1;1
GO:0060969;negative regulation of gene silencing;1/26;37/18862;0.049803049722014;0.131194144869565;0.0856748369974217;ADAR;1
GO:1901223;negative regulation of NIK/NF-kappaB signaling;1/26;37/18862;0.049803049722014;0.131194144869565;0.0856748369974217;IFI35;1
GO:0010463;mesenchymal cell proliferation;1/26;38/18862;0.0511154067316941;0.132203029228791;0.0863336773985073;STAT1;1
GO:0010742;macrophage derived foam cell differentiation;1/26;38/18862;0.0511154067316941;0.132203029228791;0.0863336773985073;STAT1;1
GO:0019692;deoxyribose phosphate metabolic process;1/26;38/18862;0.0511154067316941;0.132203029228791;0.0863336773985073;SAMHD1;1
GO:0090077;foam cell differentiation;1/26;38/18862;0.0511154067316941;0.132203029228791;0.0863336773985073;STAT1;1
GO:0002701;negative regulation of production of molecular mediator of immune response;1/26;39/18862;0.0524260208107939;0.134371197483521;0.0877495748990529;BST2;1
GO:0072210;metanephric nephron development;1/26;39/18862;0.0524260208107939;0.134371197483521;0.0877495748990529;STAT1;1
GO:0009262;deoxyribonucleotide metabolic process;1/26;40/18862;0.0537348941816127;0.135889576841501;0.0887411351864762;SAMHD1;1
GO:0031297;replication fork processing;1/26;40/18862;0.0537348941816127;0.135889576841501;0.0887411351864762;SAMHD1;1
GO:0032735;positive regulation of interleukin-12 production;1/26;40/18862;0.0537348941816127;0.135889576841501;0.0887411351864762;IRF1;1
GO:0050691;regulation of defense response to virus by host;1/26;41/18862;0.055042029063733;0.138579267864;0.09049760717046;STAT1;1
GO:0046782;regulation of viral transcription;1/26;42/18862;0.0563474276740276;0.140621431344393;0.0918312186931289;IFITM3;1
GO:2001239;regulation of extrinsic apoptotic signaling pathway in absence of ligand;1/26;42/18862;0.0563474276740276;0.140621431344393;0.0918312186931289;IFI6;1
GO:0031503;protein-containing complex localization;2/26;283/18862;0.0575707764333325;0.142623789030294;0.0931388354966124;MX2/MX1;2
GO:0034142;toll-like receptor 4 signaling pathway;1/26;43/18862;0.0576510922266567;0.142623789030294;0.0931388354966124;IFI35;1
GO:0003254;regulation of membrane depolarization;1/26;44/18862;0.0589530249330759;0.145213295181473;0.09482988289531;IFI6;1
GO:0006195;purine nucleotide catabolic process;1/26;46/18862;0.0615517036395977;0.149091944608158;0.0973627905775222;SAMHD1;1
GO:0007595;lactation;1/26;46/18862;0.0615517036395977;0.149091944608158;0.0973627905775222;OAS2;1
GO:0071354;cellular response to interleukin-6;1/26;46/18862;0.0615517036395977;0.149091944608158;0.0973627905775222;STAT1;1
GO:0051258;protein polymerization;2/26;294/18862;0.0615757591966907;0.149091944608158;0.0973627905775222;MX2/MX1;2
GO:0030857;negative regulation of epithelial cell differentiation;1/26;47/18862;0.0628484540491087;0.150255337621609;0.0981225310894974;STAT1;1
GO:0045581;negative regulation of T cell differentiation;1/26;47/18862;0.0628484540491087;0.150255337621609;0.0981225310894974;IRF1;1
GO:0045646;regulation of erythrocyte differentiation;1/26;47/18862;0.0628484540491087;0.150255337621609;0.0981225310894974;STAT1;1
GO:0035850;epithelial cell differentiation involved in kidney development;1/26;48/18862;0.0641434814312365;0.152073503893223;0.099309863794853;STAT1;1
GO:0043330;response to exogenous dsRNA;1/26;48/18862;0.0641434814312365;0.152073503893223;0.099309863794853;IFIT1;1
GO:0043124;negative regulation of I-kappaB kinase/NF-kappaB signaling;1/26;49/18862;0.0654367879839518;0.153857571747391;0.100474928918377;STAT1;1
GO:0045005;DNA-dependent DNA replication maintenance of fidelity;1/26;49/18862;0.0654367879839518;0.153857571747391;0.100474928918377;SAMHD1;1
GO:0032648;regulation of interferon-beta production;1/26;50/18862;0.0667283759025403;0.155608384789121;0.101618277366681;IRF1;1
GO:0070741;response to interleukin-6;1/26;50/18862;0.0667283759025403;0.155608384789121;0.101618277366681;STAT1;1
GO:0043900;regulation of multi-organism process;1/26;51/18862;0.0680182473796053;0.157326759182908;0.102740442126661;BST2;1
GO:0072523;purine-containing compound catabolic process;1/26;51/18862;0.0680182473796053;0.157326759182908;0.102740442126661;SAMHD1;1
GO:0070661;leukocyte proliferation;2/26;312/18862;0.0683310368881816;0.157410364329455;0.102795039512159;IRF1/BST2;2
GO:0002711;positive regulation of T cell mediated immunity;1/26;52/18862;0.0693064046050652;0.157741376881128;0.10301120347616;RSAD2;1
GO:0032608;interferon-beta production;1/26;52/18862;0.0693064046050652;0.157741376881128;0.10301120347616;IRF1;1
GO:0035196;production of miRNAs involved in gene silencing by miRNA;1/26;52/18862;0.0693064046050652;0.157741376881128;0.10301120347616;ADAR;1
GO:0002704;negative regulation of leukocyte mediated immunity;1/26;53/18862;0.0705928497661639;0.159394172686299;0.104090542888287;BST2;1
GO:0002720;positive regulation of cytokine production involved in immune response;1/26;53/18862;0.0705928497661639;0.159394172686299;0.104090542888287;RSAD2;1
GO:0043331;response to dsRNA;1/26;54/18862;0.0718775850474695;0.161653541075139;0.105565997594162;IFIT1;1
GO:0001836;release of cytochrome c from mitochondria;1/26;55/18862;0.0731606126308789;0.163248582694;0.106607621294944;IFI6;1
GO:0045620;negative regulation of lymphocyte differentiation;1/26;55/18862;0.0731606126308789;0.163248582694;0.106607621294944;IRF1;1
GO:0031050;dsRNA processing;1/26;56/18862;0.0744419346956211;0.163747388975953;0.106933361036928;ADAR;1
GO:0051289;protein homotetramerization;1/26;56/18862;0.0744419346956211;0.163747388975953;0.106933361036928;SAMHD1;1
GO:0070918;production of small RNA involved in gene silencing by RNA;1/26;56/18862;0.0744419346956211;0.163747388975953;0.106933361036928;ADAR;1
GO:0006898;receptor-mediated endocytosis;2/26;328/18862;0.0745352789890542;0.163747388975953;0.106933361036928;MX2/MX1;2
GO:0030336;negative regulation of cell migration;2/26;330/18862;0.0753234658885637;0.164842508040741;0.107648516026976;IFITM1/BST2;2
GO:0075733;intracellular transport of virus;1/26;57/18862;0.0757215534182584;0.16507878886969;0.107802816522062;BST2;1
GO:0061005;cell differentiation involved in kidney development;1/26;58/18862;0.0769994709726918;0.167224041921609;0.10920374951129;STAT1;1
GO:0000209;protein polyubiquitination;2/26;337/18862;0.0781036164724387;0.168977025752158;0.110348515568424;PSMB8/IFI27;2
GO:0016050;vesicle organization;2/26;339/18862;0.0789040061202794;0.169322755231606;0.110574290253921;MX2/MX1;2
GO:0006913;nucleocytoplasmic transport;2/26;340/18862;0.0793051989086594;0.169322755231606;0.110574290253921;MX2/IFI27;2
GO:0032615;interleukin-12 production;1/26;60/18862;0.0795502112592613;0.169322755231606;0.110574290253921;IRF1;1
GO:0032655;regulation of interleukin-12 production;1/26;60/18862;0.0795502112592613;0.169322755231606;0.110574290253921;IRF1;1
GO:0007596;blood coagulation;2/26;342/18862;0.0801095683017079;0.169322755231606;0.110574290253921;IRF2/IRF1;2
GO:0051169;nuclear transport;2/26;343/18862;0.0805127400761615;0.169322755231606;0.110574290253921;MX2/IFI27;2
GO:0070936;protein K48-linked ubiquitination;1/26;61/18862;0.0808230383259169;0.169322755231606;0.110574290253921;IFI27;1
GO:2000146;negative regulation of cell motility;2/26;345/18862;0.0813210457423862;0.169322755231606;0.110574290253921;IFITM1/BST2;2
GO:0007599;hemostasis;2/26;346/18862;0.081726174833505;0.169322755231606;0.110574290253921;IRF2/IRF1;2
GO:0045861;negative regulation of proteolysis;2/26;346/18862;0.081726174833505;0.169322755231606;0.110574290253921;IFI6/BST2;2
GO:0006521;regulation of cellular amino acid metabolic process;1/26;62/18862;0.0820941728934146;0.169322755231606;0.110574290253921;PSMB8;1
GO:0051851;modulation by host of symbiont process;1/26;62/18862;0.0820941728934146;0.169322755231606;0.110574290253921;IFI27;1
GO:0050817;coagulation;2/26;347/18862;0.0821319515710428;0.169322755231606;0.110574290253921;IRF2/IRF1;2
GO:0032386;regulation of intracellular transport;2/26;350/18862;0.0833531438059803;0.171219995760299;0.111813261499187;MX2/IFI27;2
GO:0051271;negative regulation of cellular component movement;2/26;352/18862;0.0841704665437927;0.171983040479318;0.112311559132734;IFITM1/BST2;2
GO:0016445;somatic diversification of immunoglobulins;1/26;64/18862;0.0846313731708421;0.171983040479318;0.112311559132734;SAMHD1;1
GO:0046794;transport of virus;1/26;64/18862;0.0846313731708421;0.171983040479318;0.112311559132734;BST2;1
GO:0051098;regulation of binding;2/26;357/18862;0.0862248165398816;0.174597582246237;0.11401895575418;IFIT2/IFIT1;2
GO:0030098;lymphocyte differentiation;2/26;358/18862;0.0866375608477428;0.174811248660871;0.114158488164439;RSAD2/IRF1;2
GO:0031349;positive regulation of defense response;2/26;361/18862;0.0878795003203958;0.175308570442699;0.114483258470581;IFI35/PSMB8;2
GO:0038034;signal transduction in absence of ligand;1/26;67/18862;0.0884245337733824;0.175308570442699;0.114483258470581;IFI6;1
GO:0045669;positive regulation of osteoblast differentiation;1/26;67/18862;0.0884245337733824;0.175308570442699;0.114483258470581;IFITM1;1
GO:0097192;extrinsic apoptotic signaling pathway in absence of ligand;1/26;67/18862;0.0884245337733824;0.175308570442699;0.114483258470581;IFI6;1
GO:1901224;positive regulation of NIK/NF-kappaB signaling;1/26;67/18862;0.0884245337733824;0.175308570442699;0.114483258470581;IFI35;1
GO:0050709;negative regulation of protein secretion;1/26;69/18862;0.0909449060503186;0.179057617794572;0.116931530998953;RSAD2;1
GO:0072088;nephron epithelium morphogenesis;1/26;69/18862;0.0909449060503186;0.179057617794572;0.116931530998953;STAT1;1
GO:0051881;regulation of mitochondrial membrane potential;1/26;71/18862;0.0934585771730158;0.182742028905313;0.119337593568727;IFI6;1
GO:0072028;nephron morphogenesis;1/26;71/18862;0.0934585771730158;0.182742028905313;0.119337593568727;STAT1;1
GO:0040013;negative regulation of locomotion;2/26;377/18862;0.0945947387283508;0.18393052228561;0.12011372558842;IFITM1/BST2;2
GO:0043154;negative regulation of cysteine-type endopeptidase activity involved in apoptotic process;1/26;72/18862;0.0947129051488291;0.18393052228561;0.12011372558842;IFI6;1
GO:0009166;nucleotide catabolic process;1/26;73/18862;0.0959655642476114;0.18572927230235;0.121288378730422;SAMHD1;1
GO:0071260;cellular response to mechanical stimulus;1/26;74/18862;0.0972165566010931;0.186879124006831;0.122039276245327;IRF1;1
GO:1902036;regulation of hematopoietic stem cell differentiation;1/26;74/18862;0.0972165566010931;0.186879124006831;0.122039276245327;PSMB8;1
GO:0001937;negative regulation of endothelial cell proliferation;1/26;75/18862;0.098465884338392;0.188010363048809;0.122778018973693;STAT1;1
GO:0002479;antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent;1/26;75/18862;0.098465884338392;0.188010363048809;0.122778018973693;PSMB8;1
GO:0002792;negative regulation of peptide secretion;1/26;76/18862;0.0997135495860211;0.189755885332595;0.123917912352985;RSAD2;1
GO:0033238;regulation of cellular amine metabolic process;1/26;77/18862;0.100959554467888;0.190850453462553;0.124632707561338;PSMB8;1
GO:0061418;regulation of transcription from RNA polymerase II promoter in response to hypoxia;1/26;77/18862;0.100959554467888;0.190850453462553;0.124632707561338;PSMB8;1
GO:0032102;negative regulation of response to external stimulus;2/26;394/18862;0.101891026609546;0.191927457851213;0.125336032969158;SAMHD1/ADAR;2
GO:0002709;regulation of T cell mediated immunity;1/26;78/18862;0.102203901105303;0.191927457851213;0.125336032969158;RSAD2;1
GO:0042590;antigen processing and presentation of exogenous peptide antigen via MHC class I;1/26;80/18862;0.104687628119023;0.195135795888333;0.12743120145885;PSMB8;1
GO:2000117;negative regulation of cysteine-type endopeptidase activity;1/26;80/18862;0.104687628119023;0.195135795888333;0.12743120145885;IFI6;1
GO:0001503;ossification;2/26;401/18862;0.104941218878435;0.195135795888333;0.12743120145885;IFITM1/ADAR;2
GO:0043367;CD4-positive, alpha-beta T cell differentiation;1/26;81/18862;0.105927012724971;0.195689838443209;0.127793012617617;RSAD2;1
GO:0043462;regulation of ATPase activity;1/26;81/18862;0.105927012724971;0.195689838443209;0.127793012617617;IFIT1;1
GO:0001656;metanephros development;1/26;82/18862;0.107164747545755;0.197335732535711;0.128867844945159;STAT1;1
GO:0031145;anaphase-promoting complex-dependent catabolic process;1/26;83/18862;0.108400834689728;0.197692547879664;0.12910085912778;PSMB8;1
GO:0051262;protein tetramerization;1/26;83/18862;0.108400834689728;0.197692547879664;0.12910085912778;SAMHD1;1
GO:1901292;nucleoside phosphate catabolic process;1/26;83/18862;0.108400834689728;0.197692547879664;0.12910085912778;SAMHD1;1
GO:1903131;mononuclear cell differentiation;2/26;411/18862;0.109342942889386;0.19877359266473;0.129806823070298;RSAD2/IRF1;2
GO:0006401;RNA catabolic process;2/26;414/18862;0.110673349536214;0.200551388172312;0.130967792109566;PSMB8/OAS2;2
GO:1903706;regulation of hemopoiesis;2/26;415/18862;0.111117813194695;0.200717573675497;0.131076317653224;STAT1/IRF1;2
GO:0007589;body fluid secretion;1/26;86/18862;0.112099231105579;0.201212815454493;0.131399729637288;OAS2;1
GO:0009144;purine nucleoside triphosphate metabolic process;1/26;86/18862;0.112099231105579;0.201212815454493;0.131399729637288;SAMHD1;1
GO:0030099;myeloid cell differentiation;2/26;419/18862;0.112900586448491;0.202013942418841;0.131922896445937;STAT1/ADAR;2
GO:0051899;membrane depolarization;1/26;87/18862;0.113328748574222;0.202144382253079;0.132008078688996;IFI6;1
GO:0060218;hematopoietic stem cell differentiation;1/26;88/18862;0.114556628869139;0.202430813125902;0.132195129097111;PSMB8;1
GO:0060993;kidney morphogenesis;1/26;88/18862;0.114556628869139;0.202430813125902;0.132195129097111;STAT1;1
GO:0072080;nephron tubule development;1/26;88/18862;0.114556628869139;0.202430813125902;0.132195129097111;STAT1;1
GO:0043161;proteasome-mediated ubiquitin-dependent protein catabolic process;2/26;425/18862;0.115589275912368;0.202709093394953;0.13237685684658;PSMB8/IFI27;2
GO:0042058;regulation of epidermal growth factor receptor signaling pathway;1/26;89/18862;0.115782874083234;0.202709093394953;0.13237685684658;IFI6;1
GO:1901532;regulation of hematopoietic progenitor cell differentiation;1/26;89/18862;0.115782874083234;0.202709093394953;0.13237685684658;PSMB8;1
GO:0061326;renal tubule development;1/26;90/18862;0.117007486306844;0.204224723032497;0.133366621460497;STAT1;1
GO:0051656;establishment of organelle localization;2/26;431/18862;0.118295009448851;0.205840551609775;0.134421819846916;MX2/MX1;2
GO:0051702;biological process involved in interaction with symbiont;1/26;92/18862;0.119451820131167;0.207219773337299;0.135322504834089;IFI27;1
GO:0031146;SCF-dependent proteasomal ubiquitin-dependent protein catabolic process;1/26;93/18862;0.120671545899765;0.208066998839293;0.135875775765924;PSMB8;1
GO:0051591;response to cAMP;1/26;93/18862;0.120671545899765;0.208066998839293;0.135875775765924;STAT1;1
GO:0051051;negative regulation of transport;2/26;438/18862;0.121472660014484;0.208815539420669;0.136364601638139;RSAD2/BST2;2
GO:0048661;positive regulation of smooth muscle cell proliferation;1/26;96/18862;0.12432098358502;0.212428347326957;0.138723904553539;STAT1;1
GO:1901184;regulation of ERBB signaling pathway;1/26;96/18862;0.12432098358502;0.212428347326957;0.138723904553539;IFI6;1
GO:0050830;defense response to Gram-positive bacterium;1/26;98/18862;0.126745846435233;0.21527876603477;0.140585337915593;GBP2;1
GO:0051817;modulation of process of other organism involved in symbiotic interaction;1/26;98/18862;0.126745846435233;0.21527876603477;0.140585337915593;IFI27;1
GO:0002474;antigen processing and presentation of peptide antigen via MHC class I;1/26;99/18862;0.127955855388158;0.215404975490716;0.140667757558455;PSMB8;1
GO:0002702;positive regulation of production of molecular mediator of immune response;1/26;99/18862;0.127955855388158;0.215404975490716;0.140667757558455;RSAD2;1
GO:0002824;positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains;1/26;99/18862;0.127955855388158;0.215404975490716;0.140667757558455;RSAD2;1
GO:0010972;negative regulation of G2/M transition of mitotic cell cycle;1/26;100/18862;0.129164252113624;0.216160174860741;0.141160931876499;PSMB8;1
GO:0035710;CD4-positive, alpha-beta T cell activation;1/26;100/18862;0.129164252113624;0.216160174860741;0.141160931876499;RSAD2;1
GO:0046634;regulation of alpha-beta T cell activation;1/26;101/18862;0.130371038673961;0.216903862589134;0.141646588648533;IRF1;1
GO:1902106;negative regulation of leukocyte differentiation;1/26;101/18862;0.130371038673961;0.216903862589134;0.141646588648533;IRF1;1
GO:0042116;macrophage activation;1/26;102/18862;0.131576217128973;0.2176362428674;0.142124861219484;IFI35;1
GO:0045639;positive regulation of myeloid cell differentiation;1/26;102/18862;0.131576217128973;0.2176362428674;0.142124861219484;STAT1;1
GO:0070498;interleukin-1-mediated signaling pathway;1/26;103/18862;0.132779789535937;0.2183575151617;0.142595879848451;PSMB8;1
GO:2001237;negative regulation of extrinsic apoptotic signaling pathway;1/26;103/18862;0.132779789535937;0.2183575151617;0.142595879848451;IFI6;1
GO:0002456;T cell mediated immunity;1/26;104/18862;0.133981757949609;0.219067874348642;0.143059771797374;RSAD2;1
GO:0002821;positive regulation of adaptive immune response;1/26;104/18862;0.133981757949609;0.219067874348642;0.143059771797374;RSAD2;1
GO:1903707;negative regulation of hemopoiesis;1/26;105/18862;0.135182124422223;0.220397217181218;0.143927883942225;IRF1;1
GO:0072009;nephron epithelium development;1/26;106/18862;0.136380891003501;0.221084692253539;0.144376831681619;STAT1;1
GO:1901222;regulation of NIK/NF-kappaB signaling;1/26;106/18862;0.136380891003501;0.221084692253539;0.144376831681619;IFI35;1
GO:0042110;T cell activation;2/26;474/18862;0.138146707335571;0.223057053655325;0.145664859754564;RSAD2/IRF1;2
GO:0002708;positive regulation of lymphocyte mediated immunity;1/26;108/18862;0.138773632678357;0.223057053655325;0.145664859754564;RSAD2;1
GO:0060071;Wnt signaling pathway, planar cell polarity pathway;1/26;108/18862;0.138773632678357;0.223057053655325;0.145664859754564;PSMB8;1
GO:0009141;nucleoside triphosphate metabolic process;1/26;109/18862;0.139967611858817;0.223712278504683;0.146092746854413;SAMHD1;1
GO:0043618;regulation of transcription from RNA polymerase II promoter in response to stress;1/26;109/18862;0.139967611858817;0.223712278504683;0.146092746854413;PSMB8;1
GO:1902750;negative regulation of cell cycle G2/M phase transition;1/26;111/18862;0.142350797104222;0.226321151909339;0.147796441816662;PSMB8;1
GO:0010498;proteasomal protein catabolic process;2/26;483/18862;0.142395382044891;0.226321151909339;0.147796441816662;PSMB8/IFI27;2
GO:0090175;regulation of establishment of planar polarity;1/26;112/18862;0.143540007241031;0.226682983668504;0.148032731911908;PSMB8;1
GO:2000736;regulation of stem cell differentiation;1/26;112/18862;0.143540007241031;0.226682983668504;0.148032731911908;PSMB8;1
GO:0048285;organelle fission;2/26;486/18862;0.14381820229232;0.226682983668504;0.148032731911908;MX2/MX1;2
GO:0002223;stimulatory C-type lectin receptor signaling pathway;1/26;114/18862;0.145913672703794;0.229350496597952;0.14977472074568;PSMB8;1
GO:0034404;nucleobase-containing small molecule biosynthetic process;1/26;115/18862;0.147098132086645;0.229941860322256;0.150160904067628;SAMHD1;1
GO:0043620;regulation of DNA-templated transcription in response to stress;1/26;115/18862;0.147098132086645;0.229941860322256;0.150160904067628;PSMB8;1
GO:0002220;innate immune response activating cell surface receptor signaling pathway;1/26;118/18862;0.150642041130234;0.234836496994803;0.15335729060987;PSMB8;1
GO:0002758;innate immune response-activating signal transduction;1/26;119/18862;0.151820194508948;0.235383353339486;0.153714408896196;PSMB8;1
GO:0050868;negative regulation of T cell activation;1/26;119/18862;0.151820194508948;0.235383353339486;0.153714408896196;IRF1;1
GO:0001736;establishment of planar polarity;1/26;123/18862;0.156517113556213;0.239403864552379;0.15633995779667;PSMB8;1
GO:0007164;establishment of tissue polarity;1/26;123/18862;0.156517113556213;0.239403864552379;0.15633995779667;PSMB8;1
GO:0007173;epidermal growth factor receptor signaling pathway;1/26;123/18862;0.156517113556213;0.239403864552379;0.15633995779667;IFI6;1
GO:0035821;modulation of process of other organism;1/26;123/18862;0.156517113556213;0.239403864552379;0.15633995779667;IFI27;1
GO:0051224;negative regulation of protein transport;1/26;123/18862;0.156517113556213;0.239403864552379;0.15633995779667;RSAD2;1
GO:0060147;regulation of posttranscriptional gene silencing;1/26;124/18862;0.157687429744245;0.240396726029196;0.15698833463751;ADAR;1
GO:0002698;negative regulation of immune effector process;1/26;125/18862;0.158856184511384;0.240396726029196;0.15698833463751;BST2;1
GO:0002705;positive regulation of leukocyte mediated immunity;1/26;125/18862;0.158856184511384;0.240396726029196;0.15698833463751;RSAD2;1
GO:0060966;regulation of gene silencing by RNA;1/26;125/18862;0.158856184511384;0.240396726029196;0.15698833463751;ADAR;1
GO:1904950;negative regulation of establishment of protein localization;1/26;127/18862;0.161189017780548;0.243279976438016;0.1588712083667;RSAD2;1
GO:0045667;regulation of osteoblast differentiation;1/26;128/18862;0.162353100275222;0.2443886615254;0.159595222492769;IFITM1;1
GO:0046683;response to organophosphorus;1/26;130/18862;0.164676606947997;0.247232161882349;0.161452137904854;STAT1;1
GO:0072073;kidney epithelium development;1/26;131/18862;0.165836035104058;0.248317642037393;0.162160998315049;STAT1;1
GO:0030879;mammary gland development;1/26;132/18862;0.166993915787807;0.249395113079428;0.162864628465522;OAS2;1
GO:0050729;positive regulation of inflammatory response;1/26;133/18862;0.168150250982122;0.250464640860805;0.1635630713604;IFI35;1
GO:0000724;double-strand break repair via homologous recombination;1/26;138/18862;0.173908813842683;0.257023675523342;0.167846373988974;SAMHD1;1
GO:0072006;nephron development;1/26;138/18862;0.173908813842683;0.257023675523342;0.167846373988974;STAT1;1
GO:1903038;negative regulation of leukocyte cell-cell adhesion;1/26;138/18862;0.173908813842683;0.257023675523342;0.167846373988974;IRF1;1
GO:1903531;negative regulation of secretion by cell;1/26;139/18862;0.175055917604705;0.258048749007971;0.168515786513392;RSAD2;1
GO:0000725;recombinational repair;1/26;140/18862;0.176201489689428;0.259066272954224;0.16918026889805;SAMHD1;1
GO:0001738;morphogenesis of a polarized epithelium;1/26;144/18862;0.180768500488757;0.26373660712334;0.172230177253795;PSMB8;1
GO:0014074;response to purine-containing compound;1/26;144/18862;0.180768500488757;0.26373660712334;0.172230177253795;STAT1;1
GO:0060968;regulation of gene silencing;1/26;144/18862;0.180768500488757;0.26373660712334;0.172230177253795;ADAR;1
GO:0038127;ERBB signaling pathway;1/26;145/18862;0.181906443590973;0.264718072642618;0.1728711120948;IFI6;1
GO:0016525;negative regulation of angiogenesis;1/26;146/18862;0.183042866760639;0.265016262561841;0.173065841613782;STAT1;1
GO:0045580;regulation of T cell differentiation;1/26;146/18862;0.183042866760639;0.265016262561841;0.173065841613782;IRF1;1
GO:0090263;positive regulation of canonical Wnt signaling pathway;1/26;147/18862;0.184177771946802;0.26559710494632;0.173445154094998;PSMB8;1
GO:0002218;activation of innate immune response;1/26;148/18862;0.185311161096115;0.26559710494632;0.173445154094998;PSMB8;1
GO:0070665;positive regulation of leukocyte proliferation;1/26;148/18862;0.185311161096115;0.26559710494632;0.173445154094998;BST2;1
GO:2000181;negative regulation of blood vessel morphogenesis;1/26;148/18862;0.185311161096115;0.26559710494632;0.173445154094998;STAT1;1
GO:1901343;negative regulation of vasculature development;1/26;149/18862;0.186443036152837;0.266547958721016;0.174066098286039;STAT1;1
GO:0051028;mRNA transport;1/26;152/18862;0.189829596174236;0.270709373992832;0.176783662971917;MX2;1
GO:0035567;non-canonical Wnt signaling pathway;1/26;153/18862;0.190955434255447;0.270956713444762;0.176945185174361;PSMB8;1
GO:0051250;negative regulation of lymphocyte activation;1/26;153/18862;0.190955434255447;0.270956713444762;0.176945185174361;IRF1;1
GO:0046434;organophosphate catabolic process;1/26;154/18862;0.19207976792958;0.271199473826132;0.177103717067107;SAMHD1;1
GO:2001236;regulation of extrinsic apoptotic signaling pathway;1/26;154/18862;0.19207976792958;0.271199473826132;0.177103717067107;IFI6;1
GO:0002822;regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains;1/26;155/18862;0.1932025991266;0.272109601245136;0.177698065376992;RSAD2;1
GO:0030856;regulation of epithelial cell differentiation;1/26;156/18862;0.194323929774096;0.273013126028297;0.178288101910996;STAT1;1
GO:0002706;regulation of lymphocyte mediated immunity;1/26;157/18862;0.19544376179729;0.273237101873852;0.178434366777301;RSAD2;1
GO:0006261;DNA-dependent DNA replication;1/26;157/18862;0.19544376179729;0.273237101873852;0.178434366777301;SAMHD1;1
GO:0044106;cellular amine metabolic process;1/26;158/18862;0.196562097119036;0.274127042305715;0.179015532205934;PSMB8;1
GO:0048660;regulation of smooth muscle cell proliferation;1/26;160/18862;0.198794285337783;0.274548418342715;0.179290707011337;STAT1;1
GO:0050680;negative regulation of epithelial cell proliferation;1/26;160/18862;0.198794285337783;0.274548418342715;0.179290707011337;STAT1;1
GO:0051048;negative regulation of secretion;1/26;160/18862;0.198794285337783;0.274548418342715;0.179290707011337;RSAD2;1
GO:0090501;RNA phosphodiester bond hydrolysis;1/26;160/18862;0.198794285337783;0.274548418342715;0.179290707011337;SAMHD1;1
GO:0048659;smooth muscle cell proliferation;1/26;162/18862;0.201020509765926;0.27695077495596;0.180859538543065;STAT1;1
GO:0009308;amine metabolic process;1/26;163/18862;0.202131390340582;0.277808601699979;0.181419732494853;PSMB8;1
GO:0007259;receptor signaling pathway via JAK-STAT;1/26;166/18862;0.205455128404364;0.281696308583332;0.183958555045632;STAT1;1
GO:0042129;regulation of T cell proliferation;1/26;168/18862;0.207663553097703;0.284039811809118;0.185488953045266;IRF1;1
GO:0009451;RNA modification;1/26;169/18862;0.208765550937623;0.284180857616047;0.185581061397585;ADAR;1
GO:0038095;Fc-epsilon receptor signaling pathway;1/26;169/18862;0.208765550937623;0.284180857616047;0.185581061397585;PSMB8;1
GO:0045619;regulation of lymphocyte differentiation;1/26;175/18862;0.215346654099699;0.291743443292211;0.190519721546851;IRF1;1
GO:0097696;receptor signaling pathway via STAT;1/26;175/18862;0.215346654099699;0.291743443292211;0.190519721546851;STAT1;1
GO:2000027;regulation of animal organ morphogenesis;1/26;176/18862;0.216438374921308;0.291919324030045;0.190634578452698;PSMB8;1
GO:0001936;regulation of endothelial cell proliferation;1/26;177/18862;0.217528635129594;0.291919324030045;0.190634578452698;STAT1;1
GO:0002478;antigen processing and presentation of exogenous peptide antigen;1/26;177/18862;0.217528635129594;0.291919324030045;0.190634578452698;PSMB8;1
GO:0051260;protein homooligomerization;1/26;177/18862;0.217528635129594;0.291919324030045;0.190634578452698;SAMHD1;1
GO:0030177;positive regulation of Wnt signaling pathway;1/26;179/18862;0.219704781208247;0.293455447200686;0.191637726134201;PSMB8;1
GO:0090090;negative regulation of canonical Wnt signaling pathway;1/26;179/18862;0.219704781208247;0.293455447200686;0.191637726134201;PSMB8;1
GO:0019083;viral transcription;1/26;180/18862;0.220790670823864;0.294215203041637;0.192133876003511;IFITM3;1
GO:0002695;negative regulation of leukocyte activation;1/26;182/18862;0.222958092553528;0.296409239866723;0.193566666678297;IRF1;1
GO:0006611;protein export from nucleus;1/26;183/18862;0.224039628399011;0.297152793843909;0.194052236105633;IFI27;1
GO:0010565;regulation of cellular ketone metabolic process;1/26;185/18862;0.226198359362642;0.297932561290147;0.19456145432508;PSMB8;1
GO:0019884;antigen processing and presentation of exogenous antigen;1/26;185/18862;0.226198359362642;0.297932561290147;0.19456145432508;PSMB8;1
GO:0030308;negative regulation of cell growth;1/26;185/18862;0.226198359362642;0.297932561290147;0.19456145432508;BST2;1
GO:0007219;Notch signaling pathway;1/26;186/18862;0.22727555819846;0.298660029133773;0.19503651888673;STAT1;1
GO:0043488;regulation of mRNA stability;1/26;188/18862;0.229425631855109;0.30079074775474;0.196427960331927;PSMB8;1
GO:0022408;negative regulation of cell-cell adhesion;1/26;189/18862;0.230498510379891;0.301502649209558;0.196892859441262;IRF1;1
GO:0001935;endothelial cell proliferation;1/26;191/18862;0.23263996006514;0.303605819442809;0.198266310726688;STAT1;1
GO:0048002;antigen processing and presentation of peptide antigen;1/26;194/18862;0.235841393842286;0.307079526536065;0.200534775445807;PSMB8;1
GO:0042098;T cell proliferation;1/26;195/18862;0.236905681594595;0.307682905431509;0.200928805137957;IRF1;1
GO:0002377;immunoglobulin production;1/26;198/18862;0.240090000020369;0.307682905431509;0.200928805137957;SAMHD1;1
GO:0019080;viral gene expression;1/26;198/18862;0.240090000020369;0.307682905431509;0.200928805137957;IFITM3;1
GO:0043487;regulation of RNA stability;1/26;198/18862;0.240090000020369;0.307682905431509;0.200928805137957;PSMB8;1
GO:0050657;nucleic acid transport;1/26;198/18862;0.240090000020369;0.307682905431509;0.200928805137957;MX2;1
GO:0050658;RNA transport;1/26;198/18862;0.240090000020369;0.307682905431509;0.200928805137957;MX2;1
GO:1901136;carbohydrate derivative catabolic process;1/26;198/18862;0.240090000020369;0.307682905431509;0.200928805137957;SAMHD1;1
GO:0050866;negative regulation of cell activation;1/26;200/18862;0.242205776576756;0.309655069442077;0.202216704306823;IRF1;1
GO:0051168;nuclear export;1/26;201/18862;0.243261539614426;0.309655069442077;0.202216704306823;IFI27;1
GO:0051236;establishment of RNA localization;1/26;201/18862;0.243261539614426;0.309655069442077;0.202216704306823;MX2;1
GO:0009612;response to mechanical stimulus;1/26;202/18862;0.244315888254372;0.310302992001647;0.202639822729778;IRF1;1
GO:0010389;regulation of G2/M transition of mitotic cell cycle;1/26;203/18862;0.245368824315754;0.310946238386779;0.203059887430456;PSMB8;1
GO:0050852;T cell receptor signaling pathway;1/26;204/18862;0.246420349615491;0.311584842069365;0.203476920267294;PSMB8;1
GO:0043281;regulation of cysteine-type endopeptidase activity involved in apoptotic process;1/26;205/18862;0.247470465968261;0.312218836221598;0.203890942903014;IFI6;1
GO:0071456;cellular response to hypoxia;1/26;206/18862;0.248519175186508;0.312848253719299;0.204301976806794;PSMB8;1
GO:0006006;glucose metabolic process;1/26;210/18862;0.252699976884937;0.316709882924073;0.206823769627598;OAS1;1
GO:0061013;regulation of mRNA catabolic process;1/26;210/18862;0.252699976884937;0.316709882924073;0.206823769627598;PSMB8;1
GO:0030178;negative regulation of Wnt signaling pathway;1/26;212/18862;0.254781981886509;0.318617467458074;0.208069495907317;PSMB8;1
GO:0036294;cellular response to decreased oxygen levels;1/26;214/18862;0.256858408846468;0.320509725073773;0.209305213118198;PSMB8;1
GO:1903792;negative regulation of anion transport;1/26;217/18862;0.259962621835549;0.323673373795246;0.211371197761024;RSAD2;1
GO:0002699;positive regulation of immune effector process;1/26;219/18862;0.262025166387798;0.324819868572237;0.212119903072796;RSAD2;1
GO:1902749;regulation of cell cycle G2/M phase transition;1/26;219/18862;0.262025166387798;0.324819868572237;0.212119903072796;PSMB8;1
GO:0045444;fat cell differentiation;1/26;221/18862;0.264082182962799;0.325949592420461;0.212857656321197;PSMB8;1
GO:0050670;regulation of lymphocyte proliferation;1/26;221/18862;0.264082182962799;0.325949592420461;0.212857656321197;IRF1;1
GO:0033002;muscle cell proliferation;1/26;222/18862;0.265108622705462;0.326508238786597;0.213222473946293;STAT1;1
GO:0032944;regulation of mononuclear cell proliferation;1/26;223/18862;0.266133685785379;0.326908700627685;0.213483990975068;IRF1;1
GO:0022618;ribonucleoprotein complex assembly;1/26;224/18862;0.267157373975173;0.326908700627685;0.213483990975068;ADAR;1
GO:2001234;negative regulation of apoptotic signaling pathway;1/26;224/18862;0.267157373975173;0.326908700627685;0.213483990975068;IFI6;1
GO:0042593;glucose homeostasis;1/26;229/18862;0.272255253461104;0.330652702469554;0.215928968590792;OAS1;1
GO:0051259;protein complex oligomerization;1/26;229/18862;0.272255253461104;0.330652702469554;0.215928968590792;SAMHD1;1
GO:0033500;carbohydrate homeostasis;1/26;230/18862;0.27327072941291;0.330652702469554;0.215928968590792;OAS1;1
GO:2000116;regulation of cysteine-type endopeptidase activity;1/26;230/18862;0.27327072941291;0.330652702469554;0.215928968590792;IFI6;1
GO:0048762;mesenchymal cell differentiation;1/26;231/18862;0.274284842821845;0.330652702469554;0.215928968590792;STAT1;1
GO:0071453;cellular response to oxygen levels;1/26;231/18862;0.274284842821845;0.330652702469554;0.215928968590792;PSMB8;1
GO:0071826;ribonucleoprotein complex subunit organization;1/26;231/18862;0.274284842821845;0.330652702469554;0.215928968590792;ADAR;1
GO:0006403;RNA localization;1/26;234/18862;0.277319025332528;0.332899842646009;0.217396437802315;MX2;1
GO:0019882;antigen processing and presentation;1/26;234/18862;0.277319025332528;0.332899842646009;0.217396437802315;PSMB8;1
GO:0007050;cell cycle arrest;1/26;235/18862;0.278327706100262;0.33340729425484;0.217727823276216;IRF1;1
GO:0038093;Fc receptor signaling pathway;1/26;239/18862;0.282348908718855;0.337513716514765;0.220409475404148;PSMB8;1
GO:0006469;negative regulation of protein kinase activity;1/26;243/18862;0.286348562111866;0.341577215600947;0.223063097044;ADAR;1
GO:0045926;negative regulation of growth;1/26;245/18862;0.288340342521653;0.343233587646068;0.224144771878757;BST2;1
GO:0033157;regulation of intracellular protein transport;1/26;248/18862;0.291317994128507;0.346054151689187;0.225986708993216;IFI27;1
GO:0019318;hexose metabolic process;1/26;250/18862;0.293296435937555;0.346955659144426;0.226575428134275;OAS1;1
GO:1901991;negative regulation of mitotic cell cycle phase transition;1/26;250/18862;0.293296435937555;0.346955659144426;0.226575428134275;PSMB8;1
GO:0048863;stem cell differentiation;1/26;251/18862;0.294283664213163;0.347401255056618;0.226866419452384;PSMB8;1
GO:0015931;nucleobase-containing compound transport;1/26;253/18862;0.296254144068248;0.349003329140442;0.227912635624042;MX2;1
GO:0042180;cellular ketone metabolic process;1/26;254/18862;0.297237399066057;0.34943818195989;0.228196611288208;PSMB8;1
GO:0000086;G2/M transition of mitotic cell cycle;1/26;258/18862;0.301157225974443;0.352589427118226;0.230254495925879;PSMB8;1
GO:0045637;regulation of myeloid cell differentiation;1/26;258/18862;0.301157225974443;0.352589427118226;0.230254495925879;STAT1;1
GO:0033673;negative regulation of kinase activity;1/26;267/18862;0.309900120137805;0.361722300753422;0.236218614681265;ADAR;1
GO:0006302;double-strand break repair;1/26;268/18862;0.310865035269637;0.361722300753422;0.236218614681265;SAMHD1;1
GO:1901988;negative regulation of cell cycle phase transition;1/26;268/18862;0.310865035269637;0.361722300753422;0.236218614681265;PSMB8;1
GO:0005996;monosaccharide metabolic process;1/26;272/18862;0.314711739058481;0.365450978620971;0.238653585150685;OAS1;1
GO:0034504;protein localization to nucleus;1/26;275/18862;0.317583209098376;0.368034309525409;0.240340599875071;GBP2;1
GO:0044839;cell cycle G2/M phase transition;1/26;276/18862;0.318537792224401;0.368390251576594;0.240573043763829;PSMB8;1
GO:0050708;regulation of protein secretion;1/26;279/18862;0.321393844183152;0.369784956435897;0.241483839833265;RSAD2;1
GO:1902105;regulation of leukocyte differentiation;1/26;279/18862;0.321393844183152;0.369784956435897;0.241483839833265;IRF1;1
GO:0001822;kidney development;1/26;280/18862;0.322343301216529;0.369784956435897;0.241483839833265;STAT1;1
GO:0006260;DNA replication;1/26;280/18862;0.322343301216529;0.369784956435897;0.241483839833265;SAMHD1;1
GO:0072593;reactive oxygen species metabolic process;1/26;281/18862;0.323291480861796;0.3700594085985;0.241663067681566;IFI6;1
GO:0046651;lymphocyte proliferation;1/26;282/18862;0.324238384768884;0.3700594085985;0.241663067681566;IRF1;1
GO:0016579;protein deubiquitination;1/26;283/18862;0.325184014585677;0.3700594085985;0.241663067681566;PSMB8;1
GO:0097193;intrinsic apoptotic signaling pathway;1/26;283/18862;0.325184014585677;0.3700594085985;0.241663067681566;IFI6;1
GO:0032943;mononuclear cell proliferation;1/26;285/18862;0.327071458529723;0.371464391024775;0.24258057539866;IRF1;1
GO:0060485;mesenchyme development;1/26;287/18862;0.328953825836264;0.372116753281977;0.243006593115415;STAT1;1
GO:0060828;regulation of canonical Wnt signaling pathway;1/26;287/18862;0.328953825836264;0.372116753281977;0.243006593115415;PSMB8;1
GO:0072001;renal system development;1/26;288/18862;0.329893109848552;0.372438848221878;0.24321693353496;STAT1;1
GO:0007162;negative regulation of cell adhesion;1/26;295/18862;0.336432790397217;0.379069817299042;0.247547212110928;IRF1;1
GO:0051348;negative regulation of transferase activity;1/26;296/18862;0.33736200607286;0.379365575998928;0.247740353949906;ADAR;1
GO:0006310;DNA recombination;1/26;299/18862;0.340142152169934;0.381737444940222;0.249289275855884;SAMHD1;1
GO:0070646;protein modification by small protein removal;1/26;300/18862;0.341066372610789;0.382021192943974;0.249474574247013;PSMB8;1
GO:0071496;cellular response to external stimulus;1/26;303/18862;0.343831571720319;0.384361815930965;0.251003091339618;IRF1;1
GO:0090305;nucleic acid phosphodiester bond hydrolysis;1/26;305/18862;0.345668835352919;0.385657975129041;0.251849533291188;SAMHD1;1
GO:0002791;regulation of peptide secretion;1/26;308/18862;0.348415459192529;0.387961636556848;0.253353913059971;RSAD2;1
GO:0043271;negative regulation of ion transport;1/26;319/18862;0.358391879006722;0.398290974911767;0.260099369427164;RSAD2;1
GO:0001655;urogenital system development;1/26;320/18862;0.359291507499728;0.398512412801843;0.260243976910648;STAT1;1
GO:0045930;negative regulation of mitotic cell cycle;1/26;321/18862;0.360189923032304;0.39873164631397;0.260387144850303;PSMB8;1
GO:0050851;antigen receptor-mediated signaling pathway;1/26;323/18862;0.361983121494573;0.399938633262936;0.261175353883668;PSMB8;1
GO:0042113;B cell activation;1/26;326/18862;0.364663861173751;0.402119645364078;0.26259963891133;BST2;1
GO:0050863;regulation of T cell activation;1/26;327/18862;0.365555031847547;0.40232265594053;0.262732212648242;IRF1;1
GO:0071214;cellular response to abiotic stimulus;1/26;330/18862;0.3682213380293;0.402919117958984;0.263121725352921;IRF1;1
GO:0104004;cellular response to environmental stimulus;1/26;330/18862;0.3682213380293;0.402919117958984;0.263121725352921;IRF1;1
GO:1903037;regulation of leukocyte cell-cell adhesion;1/26;330/18862;0.3682213380293;0.402919117958984;0.263121725352921;IRF1;1
GO:0006520;cellular amino acid metabolic process;1/26;331/18862;0.369107709991918;0.4031137945977;0.263248856707035;PSMB8;1
GO:0060070;canonical Wnt signaling pathway;1/26;333/18862;0.370876868077397;0.404269996046052;0.264003900849609;PSMB8;1
GO:1903311;regulation of mRNA metabolic process;1/26;334/18862;0.371759657295919;0.404457447421373;0.264126313828035;PSMB8;1
GO:0045765;regulation of angiogenesis;1/26;335/18862;0.372641255358867;0.404642889883961;0.26424741490896;STAT1;1
GO:1901342;regulation of vasculature development;1/26;341/18862;0.377905915745278;0.409578030588692;0.267470252146533;STAT1;1
GO:0042742;defense response to bacterium;1/26;344/18862;0.380522289893581;0.411629625379178;0.268810022678475;GBP2;1
GO:0001666;response to hypoxia;1/26;348/18862;0.383994334491015;0.41381207637384;0.270235247359108;PSMB8;1
GO:2001233;regulation of apoptotic signaling pathway;1/26;348/18862;0.383994334491015;0.41381207637384;0.270235247359108;IFI6;1
GO:0032956;regulation of actin cytoskeleton organization;1/26;352/18862;0.387447663424468;0.416744273135202;0.272150084944457;BST2;1
GO:0010948;negative regulation of cell cycle process;1/26;359/18862;0.393446245587785;0.421721581540304;0.275400459316858;PSMB8;1
GO:0002449;lymphocyte mediated immunity;1/26;360/18862;0.394298561299546;0.421721581540304;0.275400459316858;RSAD2;1
GO:0036293;response to decreased oxygen levels;1/26;360/18862;0.394298561299546;0.421721581540304;0.275400459316858;PSMB8;1
GO:0043687;post-translational protein modification;1/26;361/18862;0.395149725357822;0.421726581936229;0.275403724768271;PSMB8;1
GO:0001933;negative regulation of protein phosphorylation;1/26;362/18862;0.395999739256568;0.421726581936229;0.275403724768271;ADAR;1
GO:0030111;regulation of Wnt signaling pathway;1/26;365/18862;0.398542894907343;0.421726581936229;0.275403724768271;PSMB8;1
GO:0007159;leukocyte cell-cell adhesion;1/26;366/18862;0.399388323070419;0.421726581936229;0.275403724768271;IRF1;1
GO:0050727;regulation of inflammatory response;1/26;366/18862;0.399388323070419;0.421726581936229;0.275403724768271;IFI35;1
GO:0001818;negative regulation of cytokine production;1/26;367/18862;0.400232608515929;0.421726581936229;0.275403724768271;BST2;1
GO:0002460;adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains;1/26;367/18862;0.400232608515929;0.421726581936229;0.275403724768271;RSAD2;1
GO:0009306;protein secretion;1/26;367/18862;0.400232608515929;0.421726581936229;0.275403724768271;RSAD2;1
GO:0035592;establishment of protein localization to extracellular region;1/26;368/18862;0.40107575272672;0.421833832350285;0.275473763425493;RSAD2;1
GO:0050678;regulation of epithelial cell proliferation;1/26;374/18862;0.406110734869604;0.425647491168311;0.277964229733445;STAT1;1
GO:0006402;mRNA catabolic process;1/26;375/18862;0.406945931802392;0.425647491168311;0.277964229733445;PSMB8;1
GO:0071692;protein localization to extracellular region;1/26;375/18862;0.406945931802392;0.425647491168311;0.277964229733445;RSAD2;1
GO:0070482;response to oxygen levels;1/26;385/18862;0.415236023374143;0.433521646421812;0.28310635683452;PSMB8;1
GO:0032970;regulation of actin filament-based process;1/26;389/18862;0.418520762549067;0.43615075804106;0.284823268131522;BST2;1
GO:0034470;ncRNA processing;1/26;400/18862;0.427462573034914;0.444654852023521;0.290376769520494;ADAR;1
GO:0002790;peptide secretion;1/26;401/18862;0.428268876420305;0.444680639932762;0.290393610019915;RSAD2;1
GO:0001558;regulation of cell growth;1/26;406/18862;0.432284043197311;0.448032095772805;0.292582239955231;BST2;1
GO:0042326;negative regulation of phosphorylation;1/26;407/18862;0.433083816435113;0.448044893730144;0.292590597515014;ADAR;1
GO:0048732;gland development;1/26;413/18862;0.43785975350648;0.452163701896891;0.295280338117848;OAS2;1
GO:0050673;epithelial cell proliferation;1/26;428/18862;0.449630943807656;0.463478273598834;0.302669189862896;STAT1;1
GO:0042391;regulation of membrane potential;1/26;431/18862;0.451956569766161;0.465033070880553;0.303684532459227;IFI6;1
GO:0043434;response to peptide hormone;1/26;435/18862;0.455042709699193;0.467254926638386;0.305135489970124;STAT1;1
GO:0022407;regulation of cell-cell adhesion;1/26;437/18862;0.456579506521868;0.467254926638386;0.305135489970124;IRF1;1
GO:0062012;regulation of small molecule metabolic process;1/26;437/18862;0.456579506521868;0.467254926638386;0.305135489970124;PSMB8;1
GO:1901990;regulation of mitotic cell cycle phase transition;1/26;439/18862;0.458112135761927;0.467981697035075;0.305610099072022;PSMB8;1
GO:0006163;purine nucleotide metabolic process;1/26;441/18862;0.459640608270386;0.468701623845609;0.306080239048192;SAMHD1;1
GO:0072521;purine-containing compound metabolic process;1/26;460/18862;0.473955838577738;0.482434476119379;0.315048321284138;SAMHD1;1
GO:0016049;cell growth;1/26;470/18862;0.481342980783977;0.489078850118005;0.319387353790872;BST2;1
GO:0022613;ribonucleoprotein complex biogenesis;1/26;473/18862;0.483539603128159;0.490434998538186;0.32027297101837;ADAR;1
GO:1901987;regulation of cell cycle phase transition;1/26;478/18862;0.487180775863353;0.493248863818946;0.322110533582625;PSMB8;1
GO:0002429;immune response-activating cell surface receptor signaling pathway;1/26;481/18862;0.489353617748068;0.493691859040161;0.322399826549213;PSMB8;1
GO:0002757;immune response-activating signal transduction;1/26;481/18862;0.489353617748068;0.493691859040161;0.322399826549213;PSMB8;1
GO:0043312;neutrophil degranulation;1/26;485/18862;0.49223697368335;0.495721837213852;0.323725480596595;BST2;1
GO:0002283;neutrophil activation involved in immune response;1/26;488/18862;0.494389210576645;0.497009648088536;0.32456647077098;BST2;1
GO:0034660;ncRNA metabolic process;1/26;492/18862;0.497245218552429;0.498999169940621;0.32586570527988;ADAR;1
GO:0002446;neutrophil mediated immunity;1/26;499/18862;0.502205947230506;0.502910769175287;0.328420130457638;BST2;1
GO:0042119;neutrophil activation;1/26;500/18862;0.502910769175287;0.502910769175287;0.328420130457638;BST2;1
